stockrow
Friday 6 November 2026
Export PCVX’s income statement to Excel — free account
Vaxcyte, Inc.
PCVX Healthcare Biotechnology
- EPS
- −61.5%
- Free cash flow
- −92.6%
Quarter to June 2026, against a year earlier
63.82
1.90
+3.07%
Follow PCVX
Alert me
Vaxcyte, Inc. (PCVX) Total debt
Vaxcyte, Inc.'s total debt at the end of fiscal 2022 was $18.0M, up 5.88% from $17.0M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $14.0M. Vaxcyte, Inc. ranks 222nd of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $18.0M | 5.88% |
| FY2021 | $17.0M | — |
| FY2019 | $0.00 | — |
| FY2018 | $0.00 | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $14.0M | (6.67%) |
| Jun 2023 | $15.0M | (11.76%) |
| Mar 2023 | $17.0M | (5.56%) |
| Dec 2022 | $18.0M | (5.26%) |
| 7 more quarters | Free account |
Total debt against peers
| Company | Total debt |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. compare | $4.2B |
| IBRX ImmunityBio, Inc. compare | $774.4M |
| TGTX TG Therapeutics, Inc. compare | $745.4M |
| CAI Caris Life Sciences,�Inc. compare | $393.3M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $341.3M |
| TECH Bio-Techne Corp compare | $200.0M |
| TWST Twist Bioscience Corporation compare | $15.0M |
| PCVX Vaxcyte, Inc. | $14.0M |
| PTGX Protagonist Therapeutics, Inc. compare | $1.8M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt